ELIFE 润色咨询

eLife

出版年份：暂无数据 年文章数：12320 投稿命中率： 开通期刊会员，数据随心看

出版周期：Irregular 自引率：4.2% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-06-06 ms5000001730669209 来自广东省

    偏重的研究方向：基础研究;口腔;生信
    经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-07-26 xiong99686 来自浙江省

    审稿速度:6.0 | 投稿命中率:5.0
    经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-08-06 ms5000001456647023 来自香港

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向：流行病
    经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2023-10-25 ms7000001335611101 来自天津

    偏重的研究方向：生物学
    经验分享：请问是不是送审了就等于接收了？

    9

    展开9条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-06-06 ms5000001730669209 来自广东省

    偏重的研究方向：口腔;生信
    经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-05-09 darktempler 来自江苏省

    5月3号投出去，不知道编辑手里要多久，头大。。。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2022-02-17 ms3000001264860737

    这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2022-10-22 lifestar

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：基因编辑;干细胞;生命科学
    经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。

    新模式的Manuscript，主要有以下几个步骤：
    1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！
    2. Peer review：外审，这个过程大家都知道！
    3. Publication：这一步就是上线了，也就是我们通常所讲online！
    4. Author revision：作者可以决定！
    5. Version of Record：最终版本！

    15

    展开15条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2024-03-19 ms1000002034075033 来自天津

    审稿速度:2.0 | 投稿命中率:5.0
    偏重的研究方向：免疫
    经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2208556, encodeId=da172208556d8, content=偏重的研究方向：基础研究;口腔;生信<br>经验分享：请问投稿过程中under pending review阶段，稿件可以要求撤回修改吗，手稿提交出现错误, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:13:27 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2216921, encodeId=115722169212a, content=审稿速度:6.0 | 投稿命中率:5.0<br>经验分享：我的投稿从Under editorial assessment变成了 Submission needs approval 是咋回事呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fac3037990, createdName=xiong99686, createdTime=Fri Jul 26 10:28:40 CST 2024, time=2024-07-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2218721, encodeId=2a852218e21a8, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：流行病<br>经验分享：想问一下大家elife的编辑处理快吗？我的Drafting letter to authors呆了两周了，不知道咋回事, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de6d6516878, createdName=ms5000001456647023, createdTime=Tue Aug 06 10:34:05 CST 2024, time=2024-08-06, status=1, ipAttribution=香港), GetPortalCommentsPageByObjectIdResponse(id=2164734, encodeId=d40c2164e3412, content=偏重的研究方向：生物学<br>经验分享：请问是不是送审了就等于接收了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Oct 25 00:14:45 CST 2023, time=2023-10-25, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2208553, encodeId=dceb22085532e, content=偏重的研究方向：口腔;生信<br>经验分享：想知道一下投稿文件出错了，在Staff checks pending阶段可以撤回修改吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38128339497, createdName=ms5000001730669209, createdTime=Thu Jun 06 08:02:29 CST 2024, time=2024-06-06, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2203680, encodeId=ee3f22036805a, content=5月3号投出去，不知道编辑手里要多久，头大。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Thu May 09 15:15:33 CST 2024, time=2024-05-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1194347, encodeId=5c40119434ef7, content=这个杂志投稿的第一版（initial submission）可以准备的比较简单，也不需要预印本，编辑会先进行评估，如果认为你的质量可以确认送审的话才会让你改成full submission，并要求你把文章上传到biorxiv，所以还是比较人性化的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a1dc5574811, createdName=ms3000001264860737, createdTime=Thu Feb 17 09:54:41 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095302, encodeId=b47a2095302f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：基因编辑;干细胞;生命科学<br>经验分享：2022年10月20日，eLife声明：从2023年1月31日起，所有经过同行评审的文章，eLife都不会作出接受/拒绝的决定，而是直接发布在其网站上。<br><br>新模式的Manuscript，主要有以下几个步骤：<br>1. Submission：提交后，编辑决定是否送外审也就是peer review。如果这一关没通过，看样子仍旧可能是要被拒稿！<br>2. Peer review：外审，这个过程大家都知道！<br>3. Publication：这一步就是上线了，也就是我们通常所讲online！<br>4. Author revision：作者可以决定！<br>5. Version of Record：最终版本！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Oct 22 00:11:03 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2193984, encodeId=0a432193984e6, content=审稿速度:2.0 | 投稿命中率:5.0<br>偏重的研究方向：免疫<br>经验分享：有一个问题，如果需要pubmed检索到发表在这个期刊上的文章，还是得修改好了编辑满意了才行是吧，他们就只是把同行评审过程全公开？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee9b8135230, createdName=ms1000002034075033, createdTime=Tue Mar 19 03:19:04 CST 2024, time=2024-03-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=914371, encodeId=04469143e162, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：cell biology;immunology<br>经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=454, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed441503704, createdName=xuhui27, createdTime=Thu Jan 07 13:45:28 CST 2021, time=2021-01-07, status=1, ipAttribution=)]
    2021-01-07 xuhui27

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：cell biology;immunology
    经验分享：elife杂志的编辑是相对最专业的，都是领域内的大牛，他们关注的是文章是否真的有意义，而不是只关注热点。这一点是与众不同的，不像nature和cell出版社那样，都是一些年轻编辑，往往只关注热点。其他杂志的审稿意见都是几个审稿人的意见直接复制黏贴，经常出现一个审稿人说你这个地方非常很有意义而另外一个不太懂的审稿人说你这个地方有什么什么问题。elife的审稿意见是编辑统一了审稿人的意见后自己写的，提的问题基本上都切中要害，意见非常中肯，不会出现自相矛盾的审稿意见。如果能够真正努力解决编辑提出的问题，往往是可以被接收的。当时revise的时候，补实验两个月完不成，申请延后一个月，编辑慷慨地给了两个月。整体感觉他们是非常nice的。“The authors have made a good faith effort to address the concerns of the reviewers. Not all their issues have been solved, but the majority are addressed, and the story seems sufficiently strong to support publication.” 这是我之前投稿最后接收函里面的一段话。与大家共勉。

    9

    展开9条回复
共270条页码: 2/27页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分